by Nisha Cooch, PhD | Sep 10, 2019 | Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Radiology Resource Page One, Radiology Resources
Zolgensma, or onasemnogene abeparvovec, is an adeno-associated virus vector-based gene therapy that was approved by the FDA in May 2019. Given the newness of this therapy, it is important that healthcare providers are educated on specific information regarding the...
by Nisha Cooch, PhD | Jan 28, 2019 | Genetic Counselor Resource Page One, Genetic Counselor Resource Pages, Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Nutritionist Resource Page One, Nutritionist Resource Pages, Orthopedics Resource Page One, Orthopedics Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Physical Therapists Resource Page One, Physical Therapists Resource Pages, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Radiology Resource Page One, Radiology Resources, Social Worker Resource Page One, Social Worker Resource Pages, Urologist Resource Page One, Urologist Resources
At the end of 2016, the U.S. Food and Drug Administration (FDA) approved nusinersen for the treatment of spinal muscular atrophy (SMA).1 Because of the high threshold for FDA approval, an abundance of data on nusinersen and its physiological effects on SMA patients...
by Michael Nace | Jan 15, 2019 | Neurologists Resource Page Two, Neurologists Resource Pages, Nursing Resource Page Two, Nursing Resource Pages, Radiology Resource Page One, Radiology Resources
Nusinersen is the first treatment available for children with spinal muscular atrophy (SMA). Before its approval in 2016, the U.S. Food and Drug Administration had not approved the use of any drug for SMA treatment.1 While the introduction of this new drug marks...
by Michael Nace | Dec 20, 2018 | Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Nutritionist Resource Page One, Nutritionist Resource Pages, Orthopedics Resource Page One, Orthopedics Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Physical Therapists Resource Page One, Physical Therapists Resource Pages, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Radiology Resource Page Three, Radiology Resources, Social Worker Resource Page One, Social Worker Resource Pages, Urologist Resource Page Two, Urologist Resources
There is a paucity of information on awareness of and attitudes towards spinal muscular atrophy (SMA) and medical approaches to the disease.1,2 However, research into what is known about SMA has revealed that the public is largely unfamiliar with SMA, and even...
by Michael Nace | Nov 28, 2018 | Neurologists Resource Page Three, Neurologists Resource Pages, Nursing Resource Page Three, Nursing Resource Pages, Pediatricians Resource Page Two, Pediatricians Resources, Radiology Resource Page Three, Radiology Resources
In the pivotal clinical trials that support FDA approval, nusinersen was administered via intrathecal injection. However, this approach requires that patients receive multiple intrathecal injections separated in time by weeks. During each infusion, the clinician must...
by Michael Nace | Oct 8, 2018 | Neurologists Resource Page One, Neurologists Resource Pages, Radiology Resource Page One, Radiology Resources
Nusinersen (Spinraza) is the first FDA-approved antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in adults and children.1,2 The oligonucleotide is administered intrathecally2; thus, administration is not as straightforward as an...
